MPR Weekly Dose Podcast #264 — Hep B Birth Dose Study; FDA Approves Treatments for Pancreatic, Ovarian Cancer; Priority Review for Narcolepsy Treatment

Recent medical updates highlight the long-term health benefits of the universal hepatitis B birth dose, alongside FDA milestones including the approval of Optune Pax for pancreatic cancer and a pembrolizumab-based regimen for platinum-resistant ovarian cancer, and the granting of priority review to oveporexton for narcolepsy type 1.

Episode metadata supplied by the publisher feed · Published Feb 13, 2026

Embed this episode

Attribution link and audio player

Ready to play

MPR Weekly Dose Podcast #264 — Hep B Birth Dose Study; FDA Approves Treatments for Pancreatic, Ovarian Cancer; Priority Review for Narcolepsy Treatment

0:00 13:16

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of MPR Weekly Dose?

This episode is 13 minutes long.

When was this MPR Weekly Dose episode published?

This episode was published on February 13, 2026.

Can I download this MPR Weekly Dose episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!